SCHEMBL2239743

SCHEMBL2239743

O=C(CCc1ccc(O)cc1)ON1C(=O)CC(S(=O)(=O)O)C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.34
NAAA Q02083 1/20 0.34
ME2 P23368 2/20 0.33
ME1 P48163 2/20 0.33
ME3 Q16798 2/20 0.33
MGLL Q99685 2/20 0.33
CYP19A1 P11511 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SLC16A3 O15427 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TTR P02766 1/20 0.33
ESR1 P03372 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16644696 0.89 FAAH (0.35) FAAHNAAAME2ME1ME3
SCHEMBL18353698 0.89 SMN1; SMN2 (0.39) FAAHNAAAMEN1KMT2AALDH1A1
SCHEMBL18353838 0.89 FAAH (0.33) FAAH
SCHEMBL18353839 0.89 FAAH (0.33) FAAH
SCHEMBL18354237 0.89 FAAH (0.35) FAAHALDH1A1
SCHEMBL18354236 0.89 FAAH (0.33) FAAH
SCHEMBL30150862 0.88 FAAH (0.33) FAAHNAAAME2ME1ME3
SCHEMBL28455474 0.83
SCHEMBL18353699 0.83 NAAA (0.38) FAAHNAAAMGLLTDP1
SCHEMBL13939342 0.81 KMT2A (0.39) MEN1KMT2AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035279-A1 Anti-GPE antibodies, their uses and assays for weakly immunogenic molecules NEUREN PHARMACEUTICALS LTD. (NZ) 2006-02-16 US claimed
US-20250367350-A1 CROSSLINKED HYDROGEL COATED MEDICAL GRAFTS COOK BIOTECH INCORPORATED (US) 2025-12-04 US disclosed
US-20250345478-A1 PHOTOCROSSLINKABLE SYNTHETIC POLYMERS Cook Biotech Incoporated (US) 2025-11-13 US disclosed
US-20250325727-A1 PHOTOCURABLE ADHESIVES WITH FERULATED PECTIN COOK BIOTECH INCORPORATED (US) 2025-10-23 US disclosed
US-20250295834-A1 SUBTISSUE IMPLANT MATERIAL COOK BIOTECH INCORPORATED (US) 2025-09-25 US disclosed
EP-3057621-B1 POLYMERIC RADIATION-SOURCES IP LIBERTY VISION CORP (US) 2025-05-14 EP disclosed
EP-4547258-A1 NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY Transcode Therapeutics, Inc. (US) 2025-05-07 EP disclosed
US-11957933-B2 Polymeric radiation-sources IP LIBERTY VISION CORPORATION (US) 2024-04-16 US disclosed
US-20240042070-A1 NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY TRANSCODE THERAPEUTICS, INC. 2024-02-08 US disclosed
WO-2024006362-A1 NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY TRANSCODE THERAPEUTICS, INC. (US) 2024-01-04 WO disclosed
US-5928667-A Drug delivery device and method for employing the same UNIVERSITY OF MARYLAND (US) 1999-07-27 US disclosed
US-5874238-A A DNA MOLECULE ENCODING A MUTANT MAMMALIAN C-REACTIVE PROTEIN WHICH HAS AT LEAST ONE CYSTEINE DELETED OR REPLACED BY OTHER AMINO ACID, FOR BINDING AGGREGATED IMMUNOGLOBULIN AND IMMUNE COMPLEXES, TREATING INFECTIONS, ENDOTOXIC SHOCK, CANCER IMMTECH INTERNATIONAL INC. (US) 1999-02-23 US disclosed
US-5788959-A Drug delivery device and method for employing the same UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) 1998-08-04 US disclosed
WO-1996006624-A1 A MUTANT PROTEIN AND METHODS AND MATERIALS FOR MAKING AND USING IT IMMTECH INTERNATIONAL, INC. (US) 1996-03-07 WO disclosed
WO-1993020107-A1 RECOMBINANT ACTIVE FORMS OF ECEF, PROTEINS THAT ASSOCIATE THEREWITH, AND USES THEREOF BRIGHAM AND WOMEN'S HOSPITAL (US) 1993-10-14 WO disclosed
EP-0454367-A2 Growth hormone releasing factor analogs ELI LILLY AND COMPANY (US) 1991-10-30 EP disclosed
EP-0194545-B1 LABELLING OF OLIGONUCLEOTIDES MOLECULAR DIAGNOSTICS, INC. (US) 1989-12-06 EP disclosed
WO-1989002752-A1 METHOD OF DIAGNOSING BLOOD CLOTS USING FIBRIN-BINDING PROTEINS GENENTECH, INC. (US) 1989-04-06 WO disclosed
US-4808520-A HYBRIDIZING WITH NUCLEIC ACID, THEN WITH NUCLEOSIDE TRIPHOSPHATE IN PRESENCE OF ENZYME MOLECULAR DIAGNOSTICS, INC. (US) 1989-02-28 US disclosed
EP-0194545-A2 Labelling of oligonucleotides MOLECULAR DIAGNOSTICS, INC. (US) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240042070-A1 NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY MICA, NTPCR, MTREX FAAH 3807/4885NAAA 4099/4885ME2 4439/4885
US-11957933-B2 Polymeric radiation-sources RAD54L, RAD18, RAD51 FAAH 2817/4885NAAA 2530/4885ME2 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.